These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26278069)

  • 1. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
    Yada K; Nogami K; Takeyama M; Ogiwara K; Wakabayashi H; Shima M
    J Thromb Haemost; 2015 Oct; 13(10):1843-53. PubMed ID: 26278069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.
    Peerlinck K; Jacquemin MG; Arnout J; Hoylaerts MF; Gilles JG; Lavend'homme R; Johnson KM; Freson K; Scandella D; Saint-Remy JM; Vermylen J
    Blood; 1999 Apr; 93(7):2267-73. PubMed ID: 10090936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies.
    Matsumoto T; Nogami K; Ogiwara K; Shima M
    Thromb Haemost; 2012 Feb; 107(2):288-301. PubMed ID: 22234708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.
    d'Oiron R; Lavergne JM; Lavend'homme R; Benhida A; Bordet JC; Negrier C; Peerlinck K; Vermylen J; Saint-Remy JM; Jacquemin M
    Blood; 2004 Jan; 103(1):155-7. PubMed ID: 12969981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
    Suzuki H; Shima M; Arai M; Kagawa K; Fukutake K; Kamisue S; Nakai H; Morichika S; Tanaka I; Inoue M; Gale K; Tuddenham EG; Yoshioka A
    Thromb Haemost; 1997 May; 77(5):862-7. PubMed ID: 9184393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
    Saenko EL; Shima M; Gilbert GE; Scandella D
    J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
    Boylan B; Rice AS; De Staercke C; Eyster ME; Yaish HM; Knoll CM; Bean CJ; Miller CH;
    J Thromb Haemost; 2015 Jun; 13(6):1036-42. PubMed ID: 25780857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of Factor VIII A2 Domain Residues 400-409 to a Factor X-Interactive Site in the Factor Xase Complex.
    Takeyama M; Nogami K; Sasai K; Furukawa S; Shima M
    Thromb Haemost; 2018 May; 118(5):830-841. PubMed ID: 29614522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacing the factor VIII C1 domain with a second C2 domain reduces factor VIII stability and affinity for factor IXa.
    Wakabayashi H; Fay PJ
    J Biol Chem; 2013 Oct; 288(43):31289-97. PubMed ID: 24030831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
    Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
    Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.
    Nguyen PC; Lewis KB; Ettinger RA; Schuman JT; Lin JC; Healey JF; Meeks SL; Lollar P; Pratt KP
    Blood; 2014 Apr; 123(17):2732-9. PubMed ID: 24591205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism.
    Nogami K; Shima M; Nishiya K; Sakurai Y; Tanaka I; Giddings JC; Saenko EL; Yoshioka A
    Thromb Haemost; 2002 Mar; 87(3):459-65. PubMed ID: 11916079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
    Yada K; Nogami K; Shima M
    Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations.
    Loomans JI; van Velzen AS; Eckhardt CL; Peters M; Mäkipernaa A; Holmstrom M; Brons PP; Dors N; Haya S; Voorberg J; van der Bom JG; Fijnvandraat K
    J Thromb Haemost; 2017 Feb; 15(2):246-254. PubMed ID: 27943580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
    Shi Q; Schroeder JA; Kuether EL; Montgomery RR
    J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.
    Yada K; Nogami K; Wakabayashi H; Fay PJ; Shima M
    Thromb Haemost; 2013 Jun; 109(6):1007-15. PubMed ID: 23467620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of factor VIII C2 domain in factor VIII binding to factor Xa.
    Nogami K; Shima M; Hosokawa K; Suzuki T; Koide T; Saenko EL; Scandella D; Shibata M; Kamisue S; Tanaka I; Yoshioka A
    J Biol Chem; 1999 Oct; 274(43):31000-7. PubMed ID: 10521497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
    Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
    J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins.
    Pipe SW; Kaufman RJ
    J Biol Chem; 1996 Oct; 271(41):25671-6. PubMed ID: 8810344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.
    Dimitrov JD; Roumenina LT; Plantier JL; Andre S; Saboulard D; Meslier Y; Planchais C; Jacquemin M; Saint-Remy JM; Atanasov BP; Kaveri SV; Lacroix-Desmazes S
    J Thromb Haemost; 2010 Jul; 8(7):1524-31. PubMed ID: 20374449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.